10 Biggest Price Target Changes For Wednesday
Barclays lifted the price target on FactSet Research Systems Inc. (NYSE: FDS) from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.
Jefferies Downgrades ALX Oncology Holdings to Hold, Lowers Price Target to $25
Jefferies downgrades ALX Oncology Holdings (NASDAQ:ALXO) from Buy to Hold and lowers the price target from $65 to $25.
59 Biggest Movers From Yesterday
Gainers
SeaChange International, Inc. (NASDAQ: SEAC) jumped 128.8% to $1.72 following Bloomberg report suggesting that social video app Triller is in merger talks with Seachange.
ALX Oncology’s Evorpacept Data Fails To Impress At ASH Presentation
ALX Oncology Holdings Inc (NASDAQ:ALXO) presented initial clinical data from its ongoing Phase 1 / 2 trial evaluating evorpacept combined with…
40 Stocks Moving In Monday’s Mid-Day Session
Gainers
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares climbed 83.4% to $91.52. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction.
ALX Oncology Announced Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine at ASH 2021; Said Complete Remissions With Cytogenetic Responses, Hematologic Improvement, and Transfusion Independence Were…
ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the presentation of initial clinical data from its ongoing trial evaluating evorpacept in combination with azacitidine for the treatment of patients wi
75 Biggest Movers From Yesterday
Gainers
Society Pass Incorporated (NASDAQ: SOPA) surged 436.7% to settle at $48.30 on Tuesday after the company priced its IPO at $9 per share.
58 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Dover Motorsports, Inc. (NYSE: DVD) shares climbed 60.3% to $3.59 after Speedway Motorsports announced it will acquire the company for $3.61 per share in cash.
ALX Oncology Falls After Updated Data For Solid Tumors Candidate
ALX Oncology Holdings Inc (NASDAQ:ALXO) released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort…